New research results or upcoming events: Stay up-to-date on what is happening at TUM.
An attractive electric vehicle at an affordable price that provides safety and comfort combined with a reasonable driving range: that was the goal of the Visio.M project. The participating researchers at the Technische Universität München (TUM) who put together the car in collaboration with specialists from industry are now unveiling it to the public.
Large range, agile drive dynamics and excellent safety: These are the goals the Visio.M electro-mobility project strives to achieve. Researchers at the Technische Universität München (TUM) have developed a torque vectoring transmission with characteristics that are optimally adapted to electric vehicles.
Immune cells that migrate to the liver and interact there with liver tissue cells get activated by metabolic stress (e.g. through lipids of a high fat diet) and drive the development of fatty liver disease, non-alcoholic steatohepatitis and liver cancer. Scientists from the Technische Universität München (TUM), the Helmholtz Zentrum München and the Zurich University Hospital made this discovery in an animal model and in patients and thus identified the previously unknown mechanism underlying these serious and widespread diseases. The results of their research have been published as the cover story of the journal Cancer Cell.
Most tumors are only fatal if the cancer cells spread in the body and form secondary tumors, known as metastases, in other organs, such as the liver. Scientists at Klinikum rechts der Isar of Technische Universität München (TUM) have now shown that increased amounts of a particular protein in the liver create favorable conditions for the implantation of cancer cells and thus for the formation of metastases. The researchers have already succeeded in preventing these processes in an animal model.
TUM start-up develops vaccine candidates for Heliobacter pyloriImevaX GmbH is another successful start-up that originated at Technische Universität München (TUM). The biopharmaceutical company has received EUR 5.9 million in funding from the GO-Bio 2 program run by Germany’s Federal Ministry of Education and Research (BMBF). ImevaX specializes in developing highly specific vaccines against chronic infectious diseases and hospital-acquired infections. The company’s lead candidate is a vaccine that targets the Heliobacter pylori bacteria, which can cause a number of diseases in humans including gastritis, gastric ulcers and stomach cancer.
The majority of wines are produced from around 20 different types of grape, all of which have their own typical aroma. This is due to the terpenes, a diverse category of chemical substances including cholesterol and estrogen. Scientists have now identified two enzymes that determine the terpene content – and thus the aroma intensity – of grapes. The findings could play an important role in the future development of grape varieties.
People who are unable to button up their jacket or who find it difficult to insert a key in lock suffer from a condition known as apraxia. This means that their motor skills have been impaired – as a result of a stroke, for instance. Scientists in Munich have now examined the parts of the brain that are responsible for planning and executing complex actions. They discovered that there is a specific network in the brain for using tools. Their findings have been published in the Journal of Neuroscience.
Electrical engineers at the Technische Universität München (TUM) have demonstrated a new kind of building block for digital integrated circuits. Their experiments show that future computer chips could be based on three-dimensional arrangements of nanometer-scale magnets instead of transistors. As the main enabling technology of the semiconductor industry – CMOS fabrication of silicon chips – approaches fundamental limits, the TUM researchers and collaborators at the University of Notre Dame are exploring "magnetic computing" as an alternative. They report their latest results in the journal Nanotechnology.
Researchers led by Professor Stephan Sieber at the Technische Universität München (TUM) and LMU’s Professor Angelika Vollmar have identified a class of chemicals that represent a potential new weapon in the fight against malignant tumors. The compound is itself non-toxic, but it stimulates the killing of rapidly dividing cells by chemotherapeutic drugs. This sensitizing effect means that the latter can be used in lower doses, which makes it less likely that the target cells will become resistant to their lethal effect.
Multiple sclerosis, type 1 diabetes and lupus have one thing in common: They are all autoimmune diseases in which the immune cells can no longer differentiate between friend or foe and thus attack the body’s own tissue. Here, the immunoproteasome, which supplies the immune system with information on processes within the cell, plays a central role. Using a novel mechanism, chemists at Technische Universität München (TUM) have now discovered a way to inhibit its functionality, thereby laying the foundation for possible optimizations of existing medications.